“ In patients with early, relapsing–remitting multiple sclerosis, alemtuzumab was more effective than interferon beta-1a but was associated with autoimmunity, most seriously manifesting as immune thrombocytopenic purpura. The study was not powered to identify uncommon adverse events.”

NEJM abstract link here

There has been extensive media coverage of the drug on UK media sources including coverage of patients who have received the drug. Cambridge researchers showed a reduction in relapse rate and disability in 334 patients suffering from multiple sclerosis for less than 3 years.